DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Extracorporeal Photopheresis for Acute Graft Versus Host Disease

Information source: Ann & Robert H Lurie Children's Hospital of Chicago
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Graft Versus Host Disease; Cancer; Stem Cell Transplantation

Intervention: Extracorporeal Photopheresis (Procedure)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Ann & Robert H Lurie Children's Hospital of Chicago

Official(s) and/or principal investigator(s):
Morris Kletzel, MD, Principal Investigator, Affiliation: Ann & Robert H Lurie Children's Hospital of Chicago

Overall contact:
Morris Kletzel, MD, Phone: 773-880-4562, Email: djacobsohn@childrensmemorial.org

Summary

The purpose of this research study is to evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in children.

Clinical Details

Official title: Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study.

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

To evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in children.

To estimate the response rate of ECP in steroid-refractory acute GVHD in children.

Secondary outcome: To evaluate the immunological mechanisms of ECP in acute GVHD.

Eligibility

Minimum age: N/A. Maximum age: 30 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Status-post allogeneic stem cell transplant (includes cord blood transplant,

matched-unrelated-donor transplant and matched-related donor transplant) for any indication.

- HLA matching needs to be 4-6/6 by at least intermediate resolution for class I + II

for cord blood and 5-6/6 for matched related or matched unrelated donors.

- Diagnosis of grade II-IV acute GVHD with histological confirmation of at least one

organ (skin, gut, or liver) within the last 14 days. Grading of acute GVHD is per the standard Keystone criteria. Prior to enrollment, efforts should be made to rule out diagnoses that may mimic GVHD, such as drug rashes or GI infection. Patients that are being treated for acute GVHD and appear to be progressing to chronic GVHD are also eligible

- No improvement, or worsening, of acute GVHD after at least 4 days of IV

methylprednisolone dosed at, at least 2. 0mg/kg/day..

- Weight >25. 0kg.

- Adequate venous access.

Exclusion Criteria:

- Evidence of veno-occlusive disease.

- Intubated patient.

- Patient receiving dialysis.

- Age > 30.

- Total bilirubin >15mg/dL

Locations and Contacts

Morris Kletzel, MD, Phone: 773-880-4562, Email: djacobsohn@childrensmemorial.org

Children's Memorial Hospital, Chicago, Illinois 60614, United States; Recruiting
Morris Kletzel, MD, Phone: 773-880-4562, Email: MKletzel@childrensmemorial.org
Additional Information

Starting date: July 2003
Last updated: October 7, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017